Prediction and Prevention of Type I Diabetes

I 型糖尿病的预测和预防

• 批准号: 6932444
• 负责人: DOROTHY J BECKER
• 金额: $ 23.21万
• 依托单位: CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-09-29 至 2008-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6932444
• 关键词: Internet; T lymphocyte; autoantigens; blood tests; clinical trials; cooperative study; coping; diabetes education; diabetes mellitus therapy; disease /disorder prevention /control; genetic susceptibility; human subject; human therapy evaluation; immunologic assay /test; immunoregulation; immunotherapy; insulin; insulin dependent diabetes mellitus; interview; longitudinal human study; pancreatic islets; patient oriented research; peptides; psychological stressor; statistics /biometry

DESCRIPTION (provided by applicant) This is a submission from the Children?s Hospital and University of Pittsburgh in response to the TrialNet RFA. This group of investigators with extensive experience has formulated four specific aims that answer all the objectives of the TrialNet RFA. Specific Aim 1 extends the current oral arm of DPT-1. Specific Aim 2 proposes the use of T-cell immunology to assess the effectiveness of immune interventions in TrialNet. Specific Aim 3 addresses the important issue of psychosocial and educational needs of subjects screened and included in intervention studies. Specific Aim 4 is a pilot study of a high-affinity peptide with potential safe effectiveness for delaying or preventing progression of autoimmunity. The strength of the application is the expertise and experience of the investigators and well established collaboration across three centers.

描述（由申请人提供） 这是儿童医院和匹兹堡大学的意思 响应试验网RFA。这组调查员有广泛的 经验已经提出了四个特定目标，以回答所有目标 试用网RFA。特定的目标1扩展了DPT-1的当前口服臂。 特定目的2提出使用T细胞免疫学评估 免疫干预措施在试验网中的有效性。特定的目标3解决了 筛选的主题的心理和教育需求的重要问题 包括在干预研究中。特定目标4是一项试点研究 高亲和力肽具有延迟或 防止自身免疫进展。 应用的优势是 调查人员和在三个中心之间建立了良好的合作。